AUTHOR=Ahmadirad Hamid , Teymoori Farshad , Mokhtari Ebrahim , Jahromi Mitra Kazemi , Norouzzadeh Mostafa , Tavakkoli Saeed , Shahrokhtabar Tahere , Farhadnejad Hossein , Mirmiran Parvin 

TITLE=Serum C-peptide level and the risk of cardiovascular diseases mortality and all-cause mortality: a meta-analysis and systematic review

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1205481

DOI=10.3389/fcvm.2023.1205481

ISSN=2297-055X

ABSTRACT=Aims and background: Recently, the serum of C-peptide has been the focus of researchers as a possible predictor of mortality. However, the possible association of serum C-peptide with cardiovascular diseases (CVDs) mortality and all-cause mortality has not been clearly identified. This meta-analysis aimed to assess the relationship between serum C-peptide and the risk of CVDs mortality and all-cause mortality.Methods: A comprehensive and systematic search was performed in various important databases, including PubMed, Web of Science, and Scopus to find relevant studies up to November 2022. The reported HR (95%CI) for all studies was converted into log HR, and their SD was calculated. Then to compute the pooled HR, the random-effects model with inverse variance weighting method was performed. Results: Twenty-three studies were included in the meta-analysis. Fourteen studies reported HR for all-cause mortality and nine studies for CVDs-related mortality. Pooled results indicate a significant association between serum C-peptide and risk of all-cause mortality (HR:1.22;95%CI:1.12-1.32, I 2 =76.8%;P-value<0.001). Also, higher serum C-peptide was related to the increased risk of CVDs mortality (HR: 1.38; 95%CI:1.08-1.77, I 2 =81.8%; P-value=0.012).Our investigation suggested that an increased serum C-peptide level is associated with a higher risk of both CVDs and all-cause mortality. Further large-scale studies and sufficient samples are recommended to present a convincing link between C-peptide and CVDs and all-cause mortality risk.